

**Florida Department of Health  
HIV/AIDS Section  
October 2020 Provider Capacity Survey Results**



The Department of Health HIV/AIDS Section and members from the Florida Comprehensive Planning Network Medication Access Committee and Community HIV/AIDS Group developed the Provider Capacity Survey to determine how HIV care providers in our communities will respond to injectable antiretroviral (ARV) therapy as a new therapeutic option. Ryan White Part A and B lead agencies distributed the survey to providers.

We obtained 74 completed surveys: 42 from Ryan White Part A recipients and 32 from Ryan White Part B recipients. Following are the results from these surveys.

Summary: Most respondents are practitioners or medical staff, associated with the health department or a federally qualified health care center, and associated with a Ryan White provider. Over 50 percent of respondents provide care for 21–500 people with HIV. A significant majority of respondents indicate readiness to provide injectable ARV therapy. About half of the respondents anticipate 25 percent or more of their patients would benefit from long-acting injectable ARVs, and about half of respondents would start the use of these medications either immediately or within 3–6 months of availability. Most respondents reported clients already expressing an interest in long-acting injectable ARVs.

<b>Respondent Locations</b>			
<b>City</b>	<b>Number of Respondents</b>	<b>City</b>	<b>Number of Respondents</b>
Arcadia	3	Pensacola	1
Bartow	3	Pompano Beach	1
Daytona Beach	2	Safety Harbor	1
Delray Beach	1	Saint Petersburg	2
Fort Lauderdale	3	Sarasota	4
Fort Myers	1	Tallahassee	2
Fort Pierce	1	Tampa	1
Gainesville	3	Vero Beach	1
Green Cove Springs	1	West Palm Beach	1
Homestead	1		
Immokalee	1		
Jacksonville	7		
Lakeland	1		
Marathon	1		
Marianna	1		
Miami	19		
Naples	1		
New Port Richey	1		
Oakland Park	1		
Okeechobee	1		
Orlando	2		
<b>Total</b>			<b>74</b>

Florida Department of Health  
HIV/AIDS Section  
October 2020 Provider Capacity Survey Results




<b>Respondent Provider Titles</b>	
<b>Title</b>	<b>Number of Respondents</b>
APRN	14
CEO	2
CHD Director/MD/ APRN	1
COO	2
Director	4
Director of Administration	1
Director of Client Services	1
DIS	1
DO	1
DO, CMO	1
DO, MBA	1
DO, Medical Director	1
Executive Vice President of HIV Services	1
HAPC	2
Health Educator/Re-Engagement Specialist	1
HIV Program Manager	2
MD	15
MD, Medical Director	1
MD, MPH	1
Not provided	6
NP	1
Operations manager	1
PA	3
Pharmacist	1
Program Manager	1
Promotion Manager	1
RN	2
RN, Clinic Supervisor	1
RN, COO	1
RN, director of nursing	1
RN, Nursing Director	1
RPh	1
<b>Total</b>	<b>74</b>



Florida Department of Health  
HIV/AIDS Section  
October 2020 Provider Capacity Survey Results





Respondent Organization or Practice Types	
Organization/Practice	Number of Respondents
AHF	10
Care Resource	1
CBO	4
Clinic	8
FQHC	11
Health Care Center	1
Health Department	30
Hospital	3
Midway Specialty Care	1
Monarch Health Services	1
Substance Abuse Center	1
UF	1
UF Cares	1
University	1
<b>Total</b>	<b>74</b>





Florida Department of Health  
HIV/AIDS Section  
October 2020 Provider Capacity Survey Results





Florida Department of Health  
HIV/AIDS Section  
October 2020 Provider Capacity Survey Results




Florida Department of Health  
HIV/AIDS Section  
October 2020 Provider Capacity Survey Results



Florida Department of Health  
HIV/AIDS Section  
October 2020 Provider Capacity Survey Results



Florida Department of Health  
HIV/AIDS Section  
October 2020 Provider Capacity Survey Results



Florida Department of Health  
HIV/AIDS Section  
October 2020 Provider Capacity Survey Results



Do you see other potential limitations with the provision of long acting injectable ARVs?

The top five responses:

1. Patient Adherence
2. Staff Training
3. Transportation
4. Medication Costs
5. Billing Concerns